Connection

Michael Hallek to Disease Progression

Back to Details
This is a "connection" page, showing publications Michael Hallek has written about Disease Progression.
Michael Hallek
Connection Strength
0.080
Disease Progression
  1. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematol. 2017 Oct; 4(10):e475-e486.
    View in: PubMed
    Score: 0.045
  2. Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. J Clin Oncol. 2019 06 01; 37(16):1391-1402.
    View in: PubMed
    Score: 0.013
  3. Lamin B1 regulates somatic mutations and progression of B-cell malignancies. Leukemia. 2018 02; 32(2):364-375.
    View in: PubMed
    Score: 0.011
  4. Defects of beta 2-adrenergic signal transduction in chronic lymphocytic leukaemia: relationship to disease progression. Eur J Clin Invest. 1997 Feb; 27(2):121-7.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.